Home Stock

Stock Research: ST Pharm

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

ST Pharm

KOE:237690 KR7237690003
92
  • Value
    39
  • Growth
    79
  • Safety
    Safety
    50
  • Combined
    68
  • Sentiment
    96
  • 360° View
    360° View
    92
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

STPharm Co.,Ltd. is a Korea-based company primarily engaged in the manufacture of pharmaceutical products, including generic active pharmaceutical ingredients (APIs) like tipepidine hibenzate, doxifluridine, clopidogrel bisulfate, and voriconazole, as well as new medicine APIs. The company operates in the pharmaceutical industry and distributes its products within the domestic market and to overseas markets. In the last fiscal year, the company had a market cap of $1278 million, profits of $65 million, and revenue of $185 million.

more

ANALYSIS: With an Obermatt 360° View of 92 (better than 92% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock ST Pharm are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for ST Pharm. The consolidated Growth Rank has a good rank of 79, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 79% of competitors in the same industry. The consolidated Safety Rank at 50 means that the company has a financing structure that is safer than 50% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 96, which means that professional investors are more optimistic about the stock than for 96% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 39, meaning that the share price of ST Pharm is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 61% of alternative stocks in the same industry. ...read more

more
Strongest Rank Price vs. Earnings (P/E)
Weakest Rank Sentiment
Country South Korea
Industry Pharmaceuticals
Size Small
Website stpharm.co.kr
Index
ST Pharm stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 20-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
39 14 12 9
Growth
79 96 51 99
Safety
Safety
50 20 20 8
Sentiment
96 52 39 98
360° View
360° View
92 55 10 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
60 76 82 93
Opinions Change
75 28 67 83
Pro Holdings
n/a 22 4 51
Market Pulse
85 80 41 72
Sentiment
96 52 39 98
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
39 14 12 9
Growth
79 96 51 99
Safety Safety
50 20 20 8
Combined
68 30 6 28
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
26 13 17 7
Price vs. Earnings (P/E)
16 19 19 5
Price vs. Book (P/B)
28 17 20 7
Dividend Yield
73 30 33 23
Value
39 14 12 9
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
81 96 67 91
Profit Growth
48 82 73 93
Capital Growth
20 52 48 21
Stock Returns
94 84 15 99
Growth
79 96 51 99
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
67 26 29 28
Refinancing
30 33 37 15
Liquidity
67 90 24 4
Safety Safety
50 20 20 8

Similar Stocks

Discover high‑ranked alternatives to ST Pharm and broaden your portfolio horizons.

Inpex

TYO:1605
Country: Japan
Industry: Oil & Gas Production
Size: X-Large
Full Stock Analysis

Hyundai Home Shopping Network

KSC:057050
Country: South Korea
Industry: Internet Retail
Size: Medium
Full Stock Analysis

Tsumura

TYO:4540
Country: Japan
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Hankook Tire

KSC:000240
Country: South Korea
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews